Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar
The progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT). Several clinical studies highlighted the striking clinical activity of T cells engineered t...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.589381/full |
id |
doaj-ae47105da2384cf2aac3a940c8293fae |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bella Guerrouahen Muhammad Elnaggar Anjud Al-Mohannadi Dhanya Kizhakayil Chiara Bonini Reuben Benjamin Renier Brentjens Christian J. Buchholz Giulia Casorati Soldano Ferrone Frederick L. Locke Francisco Martin Axel Schambach Axel Schambach Cameron Turtle Paul Veys Hans J. van der Vliet Hans J. van der Vliet Cristina Maccalli The EICCI Faculty Group |
spellingShingle |
Bella Guerrouahen Muhammad Elnaggar Anjud Al-Mohannadi Dhanya Kizhakayil Chiara Bonini Reuben Benjamin Renier Brentjens Christian J. Buchholz Giulia Casorati Soldano Ferrone Frederick L. Locke Francisco Martin Axel Schambach Axel Schambach Cameron Turtle Paul Veys Hans J. van der Vliet Hans J. van der Vliet Cristina Maccalli The EICCI Faculty Group Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar Frontiers in Immunology cancer immunotherapy CAR-T cells TCR engineered lymphocytes CAR-NK cells monoclonal antibody |
author_facet |
Bella Guerrouahen Muhammad Elnaggar Anjud Al-Mohannadi Dhanya Kizhakayil Chiara Bonini Reuben Benjamin Renier Brentjens Christian J. Buchholz Giulia Casorati Soldano Ferrone Frederick L. Locke Francisco Martin Axel Schambach Axel Schambach Cameron Turtle Paul Veys Hans J. van der Vliet Hans J. van der Vliet Cristina Maccalli The EICCI Faculty Group |
author_sort |
Bella Guerrouahen |
title |
Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar |
title_short |
Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar |
title_full |
Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar |
title_fullStr |
Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar |
title_full_unstemmed |
Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar |
title_sort |
proceedings from the first international workshop at sidra medicine: “engineered immune cells in cancer immunotherapy (eicci): from discovery to off-the-shelf development”, 15th–16th february 2019, doha, qatar |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2021-01-01 |
description |
The progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT). Several clinical studies highlighted the striking clinical activity of T cells engineered to express either Chimeric Antigen (CAR) or T Cell (TCR) Receptors to target molecularly defined antigens expressed on tumor cells. The breakthrough of immunotherapy is represented by the approval of CAR-T cells specific for advanced or refractory CD19+ B cell malignancies by both the Food and Drug Administration (FDA) and the European Medicinal Agency (EMA). Moreover, advances in the manufacturing and gene editing of engineered immune cells contributed to the selection of drug products with desired phenotype, refined specificity and decreased toxicity. An important step toward the optimization of CAR-T cell therapy is the development of “off-the shelf” T cell products that allow to reduce the complexity and the costs of the manufacturing and to render these drugs available for a broad number of cancer patients. The Engineered Immune Cells in Cancer Immunotherapy (EICCI) workshop hosted in Doha, Qatar, renowned experts, from both academia and industry, to present and discuss the progress on both pre-clinical and clinical development of genetically modified immune cells, including advances in the “off-the-shelf” manufacturing. These experts have addressed also organizational needs and hurdles for the clinical grade production and application of these biological drugs. |
topic |
cancer immunotherapy CAR-T cells TCR engineered lymphocytes CAR-NK cells monoclonal antibody |
url |
https://www.frontiersin.org/articles/10.3389/fimmu.2020.589381/full |
work_keys_str_mv |
AT bellaguerrouahen proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT muhammadelnaggar proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT anjudalmohannadi proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT dhanyakizhakayil proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT chiarabonini proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT reubenbenjamin proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT renierbrentjens proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT christianjbuchholz proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT giuliacasorati proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT soldanoferrone proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT frederickllocke proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT franciscomartin proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT axelschambach proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT axelschambach proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT cameronturtle proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT paulveys proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT hansjvandervliet proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT hansjvandervliet proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT cristinamaccalli proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar AT theeiccifacultygroup proceedingsfromthefirstinternationalworkshopatsidramedicineengineeredimmunecellsincancerimmunotherapyeiccifromdiscoverytoofftheshelfdevelopment15th16thfebruary2019dohaqatar |
_version_ |
1724338482852134912 |
spelling |
doaj-ae47105da2384cf2aac3a940c8293fae2021-01-14T05:30:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-01-011110.3389/fimmu.2020.589381589381Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, QatarBella Guerrouahen0Muhammad Elnaggar1Anjud Al-Mohannadi2Dhanya Kizhakayil3Chiara Bonini4Reuben Benjamin5Renier Brentjens6Christian J. Buchholz7Giulia Casorati8Soldano Ferrone9Frederick L. Locke10Francisco Martin11Axel Schambach12Axel Schambach13Cameron Turtle14Paul Veys15Hans J. van der Vliet16Hans J. van der Vliet17Cristina Maccalli18The EICCI Faculty GroupResearch Department, Sidra Medicine, Doha, QatarResearch Department, Sidra Medicine, Doha, QatarResearch Department, Sidra Medicine, Doha, QatarResearch Department, Sidra Medicine, Doha, QatarExperimental Hematology Unit, University Vita-Salute San Raffaele and Hospital San Raffaele Scientific Institute, Milan, ItalyDivision of Cancer Studies, King’s College Hospital, London, United KingdomCellular Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesResearch Unit for Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, GermanyExperimental Immunology Unit, University Vita-Salute San Raffaele and Hospital San Raffaele Scientific Institute, Milan, ItalyDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, United StatesPfizer/University of Granada/Andalusian Regional Government, Genomic Medicine Department, Granada, Spain0Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany1Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boson, MA, United States2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States3Bone Marrow Transplant Unit, Great Ormond Street (GOS) Hospital, and University College London GOS Institute of Child Health, London, United Kingdom4Hans van Der Vliet, Department of Medical Oncology, Amsterdam UMC, VU University and Cancer Center, Amsterdam, Netherlands5Lava Therapeutics, Utrecht, NetherlandsResearch Department, Sidra Medicine, Doha, QatarThe progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT). Several clinical studies highlighted the striking clinical activity of T cells engineered to express either Chimeric Antigen (CAR) or T Cell (TCR) Receptors to target molecularly defined antigens expressed on tumor cells. The breakthrough of immunotherapy is represented by the approval of CAR-T cells specific for advanced or refractory CD19+ B cell malignancies by both the Food and Drug Administration (FDA) and the European Medicinal Agency (EMA). Moreover, advances in the manufacturing and gene editing of engineered immune cells contributed to the selection of drug products with desired phenotype, refined specificity and decreased toxicity. An important step toward the optimization of CAR-T cell therapy is the development of “off-the shelf” T cell products that allow to reduce the complexity and the costs of the manufacturing and to render these drugs available for a broad number of cancer patients. The Engineered Immune Cells in Cancer Immunotherapy (EICCI) workshop hosted in Doha, Qatar, renowned experts, from both academia and industry, to present and discuss the progress on both pre-clinical and clinical development of genetically modified immune cells, including advances in the “off-the-shelf” manufacturing. These experts have addressed also organizational needs and hurdles for the clinical grade production and application of these biological drugs.https://www.frontiersin.org/articles/10.3389/fimmu.2020.589381/fullcancerimmunotherapyCAR-T cellsTCR engineered lymphocytesCAR-NK cellsmonoclonal antibody |